POPULATION PHARMACOKINETICS OF AMIKACIN IN INTENSIVE-CARE UNIT PATIENTS STUDIED BY NPEM ALGORITHM

被引:16
|
作者
DEBORD, J
PESSIS, C
VOULTOURY, JC
MARQUET, P
LOTFI, H
MERLE, L
LACHSATRE, G
机构
[1] HOP DUPUYTREN,SERV PHARMACOL TOXICOL,F-87042 LIMOGES,FRANCE
[2] HOP DUPUYTREN,SERV REANIMAT POLYVALENTE,F-87042 LIMOGES,FRANCE
[3] FAC PHARM LIMOGES,TOXICOL LAB,F-87025 LIMOGES,FRANCE
关键词
AMIKACIN; POPULATION PHARMACOKINETICS; NPEM ALGORITHM; BAYESIAN ESTIMATION; PREDICTIVE PERFORMANCE;
D O I
10.1111/j.1472-8206.1995.tb00266.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The population pharmacokinetics of amikacin was studied in 40 intensive care unit patients (212 plasma concentrations) by NPEM algorithm using a one-compartment model. The population was best characterized by the following pharmacokinetic parameters: renal clearance relative to creatinine clearance (C-s = 0.96 +/- 0.33), and either the total volume of distribution (V-d = 23.9 +/- 7.01) or the volume of distribution relative to body weight (V-s = 0.36 +/- 0.10 l.kg(-1). The volume of distribution was increased with respect to the usual value of 0.25 l.kg(-1). The statistical distribution of these pharmacokinetic parameters was approximately gaussian, with no significant correlation between volume of distribution and clearance. The medians and standard deviations of C-s and V-s were used as reference population values to estimate the pharmacokinetics of amikacin in a second group of 29 patients by the bayesian method, with two blood samples per patient. For each patient, the fitted parameters were able to predict the plasma concentrations of amikacin during the next 72 h with no significant bias and good precision (2.9 mg.l(-1) for peaks and 0.5 mg.l(-1) for troughs). This study confirms the ability of the NPEM algorithm to provide reference population values for use in bayesian monitoring of aminoglycoside therapy.
引用
收藏
页码:57 / 61
页数:5
相关论文
共 50 条
  • [41] Optimization of Micafungin Dosage for Chinese Patients with Sepsis in the Intensive Care Unit Based on a Population Pharmacokinetic-Pharmacodynamic Analysis
    Zhong, Shubai
    Zhu, Xu
    Zhao, Limei
    Song, Yan
    Yu, Jian
    Zheng, Zhen
    Zang, Bin
    PHARMACEUTICAL RESEARCH, 2021, 38 (01) : 67 - 77
  • [42] Large inter-individual variability in pharmacokinetics of dexmedetomidine and its two major N-glucuronides in adult intensive care unit patients
    Yang, Mengbi
    Tse, Andrew H. W.
    Lee, Anna
    Joynt, Gavin M.
    Zuo, Zhong
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2019, 175
  • [43] Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis
    An, Guohua
    Creech, C. Buddy
    Wu, Nan
    Nation, Roger L.
    Gu, Kenan
    Nalbant, Demet
    Jimenez-Truque, Natalia
    Fissell, William
    Rolsma, Stephanie
    Patel, Pratish C.
    Watanabe, Amy
    Fishbane, Nicholas
    Kirkpatrick, Carl M. J.
    Landersdorfer, Cornelia B.
    Winokur, Patricia
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (01)
  • [44] NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit
    Jaruratanasirikul, Sutep
    Boonpeng, Apinya
    Nawakitrangsan, Monchana
    Samaeng, Maseetoh
    PHARMACOTHERAPY, 2021, 41 (07): : 572 - 597
  • [45] Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling
    Su, Wei
    Song, Shuping
    Liu, Jieqiong
    Yu, Haitao
    Feng, Binbin
    Wu, Yinshan
    Guo, Feng
    Yu, Zhenwei
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [46] Population Pharmacokinetics of Vancomycin in Intensive Care Patients with the Time-Varying Status of Temporary Mechanical Circulatory Support or Continuous Renal Replacement Therapy
    Tsai, Meng-Ta
    Wang, Wei-Chun
    Roan, Jun-Neng
    Luo, Chwan-Yau
    Chou, Chen-Hsi
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (12) : 2617 - 2635
  • [47] Potential Factors for Inadequate Voriconazole Plasma Concentrations in Intensive Care Unit Patients and Patients with Hematological Malignancies
    Hoenigl, Martin
    Duettmann, Wiebke
    Raggam, Reinhard B.
    Seeber, Katharina
    Troppan, Katharina
    Fruhwald, Sonja
    Prueller, Florian
    Wagner, Jasmin
    Valentin, Thomas
    Zollner-Schwetz, Ines
    Woelfler, Albert
    Krause, Robert
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (07) : 3262 - 3267
  • [48] Safety and Efficacy of Tigecycline in Intensive Care Unit Patients Based on Therapeutic Drug Monitoring
    Fan, Guangjun
    Jin, Liu
    Bai, Hansheng
    Jiang, Kang
    Xie, Jiao
    Dong, Yalin
    THERAPEUTIC DRUG MONITORING, 2020, 42 (06) : 835 - 840
  • [49] Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit; targeting postoperative, ECMO and hypothermia patients
    Zeilmaker, Gerdien A.
    Pokorna, Paula
    Mian, Paola
    Wildschut, Enno D.
    Knibbe, Catherijne A. J.
    Krekels, Elke H. J.
    Allegaert, Karel
    Tibboel, Dick
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (04) : 417 - 428
  • [50] Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?
    Nicolau, David P.
    Dimopoulos, George
    Welte, Tobias
    Luyt, Charles-Edouard
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (08) : 907 - 918